Want to see IL:CANF full AI Analyst Report?
Top Page
Can Fite Bio
(TASE:CANF)
Select Model
Select Model
Rating:40Underperform
Price Target:
329.00
▼(-36.14% Downside)
Action:Downgraded
Date:09/14/26
The score is primarily weighed down by weak financial performance—minimal revenue, persistent large losses, and substantial cash burn—despite low leverage. Technicals also remain negative with the stock trading below major moving averages and a bearish MACD, though momentum indicators show the shares are heavily oversold. Valuation provides limited support given the negative P/E and no dividend yield.
Positive Factors
Low leverage
Very low debt limits interest obligations and reduces near-term balance-sheet pressure. This gives Can-Fite more flexibility to direct available capital toward clinical development, although it does not eliminate the need to fund ongoing operating losses.
Negative Factors
Minimal and declining revenue
Very small and declining revenue shows that the company has not yet established a durable commercial earnings base. With product revenue insufficient to support the cost structure, future financial performance remains heavily dependent on successful clinical progress or monetization of candidates.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt limits interest obligations and reduces near-term balance-sheet pressure. This gives Can-Fite more flexibility to direct available capital toward clinical development, although it does not eliminate the need to fund ongoing operating losses.
Read all positive factors
Can Fite Bio (CANF) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪21.00M
Dividend YieldN/A
Average Volume (3M)25.27K
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue GrowthN/A
EPS GrowthN/A
CountryIL
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.54
Shares Outstanding6,063,093
10 Day Avg. Volume52,690
30 Day Avg. Volume25,268
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Can Fite Bio Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liv...
How the Company Makes Money
As a clinical-stage biotech, Can-Fite has not consistently generated recurring product revenue from marketed drugs. The company’s primary sources of cash have typically been (1) external financing (e.g., public offerings or other capital raises) a...
Can Fite Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 405.00K | 438.40K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 405.00K | 412.42K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -9.73M | -10.74M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -9.55M | -10.64M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 8.05M | 9.52M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.04M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 49.00K | 71.01K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.20M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.86M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -9.51M | -9.69M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -9.51M | -9.69M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -4.00M | -2.16K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.04M | 10.44M | 6.71M | 9.14M | 0.00 | 20.46M |
Can Fite Bio Technical Analysis
Negative
515.20
Price Trends
491.99
Negative
482.48
Negative
916.08
Negative
Market Momentum
-44.26
Positive
24.23
Positive
2.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 515.2 is above the 20-day moving average (MA) of 456.64, above the 50-day MA of 491.99, and below the 200-day MA of 916.08, indicating a bearish trend. The MACD of -44.26 indicates Positive momentum. The RSI at 24.23 is Positive, neither overbought nor oversold. The STOCH value of 2.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.
Can Fite Bio Risk Analysis
Can Fite Bio disclosed 68 risk factors in its most recent earnings report. Can Fite Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can Fite Bio Peers Comparison
UnderperformOutperform
Sector (55)
IL:CANF
Can Fite Bio
349.70
348.70
34870.00%
IL:HDST.M
Hadasit Bio
57.30
2.60
4.75%
IL:XTLB
Xtl Bio
1.80
-2.70
-60.00%
IL:BLRX
Bioline Rx
1.30
-0.90
-40.91%
IL:GEFR
Cannomed
77.50
5.20
7.19%
IL:MTLF
Matricelf
262.30
-392.20
-59.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.